IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-25 (lifesciencereport.com)
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance -
Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million LINZESS (Iinaclotide) EUTRx ...
Read more
2025-04-17 (pharmabiz.com)
Abbott with IQVIA highlights reality of vertigo in India
Abbott in collaboration with IQVIA highlights that 44% of people have been living with vertigo for more than a year, experiencing episodes once a week. Many mistake vertigo for low blood sugar, low blood pressure, dehydration, or stress. Only 48% of those with dizziness get. Even after diagnosis, people often delay seeking medical help until it's absolutely necessary.
Read more
2025-04-14 (equitypandit.com)
Aurobindo Pharma Gets USFDA Green Light for Generic Xarelto -
Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rivaroxaban Tablets
Read more
2025-04-09 (fena.ba)
Health Ministry of Health and Representatives of IQVIA-conversation on the development of the oncological network and register in FBiH
Sarajevo, 9. April (Fena) - The Health Minister Sarajevo Enis Hasanović held a meeting with the representatives of Iqvia, international companies specializing in the application of data, technology and health care analytics. The meeting was attended by the director of the representative office of IQVIA in BiH Salih Valjevac and Kaspars Gros. The topic of the meeting was the need to establish an oncological network and an oncological register in the Federation of BiH with the aim of improving health care for oncological patients.
Read more
2025-04-09 (pharma-fakten.de)
Clinical studies: Research on the drugs of tomorrow
Over 5,300 clinical studies have been restarted in 2024 worldwide. The focus is oncology, immunology, neurology and cardiovascular diseases.
Read more
2025-04-07 (biopharmatrend.com)
IQVIA Introduces a Compact Medical Reasoning LLM Outscoring Larger Models
Purpose-built for healthcare, the 8B-parameter model delivers strong accuracy with low deployment costs, showing promise in clinical reasoning, therapeutic evaluation, and evidence-based decision support.
Read more
2025-04-04 (fiercehealthcare.com)
PAI report: Rural areas rapidly losing independent docs, practices
Rural areas are quickly losing independent physicians and medical practices amid the corporatization of healthcare, a new report finds. | The number of independent doctors in rural areas fell 43% from 2019 through 2023, while rural areas lost 5% of all practicing physicians.
Read more
2025-04-03 (biomedcentral.com)
Chronic hepatitis B virus infection increases the risk of kidney disease while antiviral therapy for hepatitis B virus can decrease kidney disease risk | BMC Nephrology | Peer Review
Extrahepatic manifestations of chronic hepatitis B virus (HBV) infection include development of kidney disease (KD). While anti-HBV treatment reduces the risk of liver-related events, the impact of HBV treatment on KD remains unclear. Using a large US-based electronic medical record (EMR) database, we examined whether patients with HBV are at higher risk of developing KD, whether the development of KD is associated with HBV-related liver disease, and whether anti-HBV treatment mitigates these risks. Data were queried from the IQVIA Ambulatory EMR database from 2006 to 2020. Propensity score matching was performed to better ensure balance across analyses. A Cox proportional hazards model was used to estimate hazard ratios (HRs) with 95% CIs for onset of KD between groups. Among patients with and without HBV (n = 11,772 each), those with HBV were more than twice as likely to develop KD vs. matched controls without HBV infection (HR, 2.18 [95% CI, 1.90–2.50]; p < 0.001); most events occurred after age 55 years.
Read more
2025-04-02 (politico.eu)
Equitable access to innovation: Understanding healthcare system readiness to deliver CAR T-cell therapy in Europe –
A new IQVIA Institute for Human Data Sciences report highlights discrepancies in healthcare systems to deliver innovative cancer treatments across Europe. We can pave a pathway to overcome the access challenges identified and fulfil the promise of advanced therapies.
Read more
2025-03-21 (zorginnovatie.nl)
National AI in Surge Congress |
On May 20, 2025, the very first National AI in Healthcare Congress takes place in the Muziekgebouw aan 't IJ in Amsterdam. This congress is organized by the NL AIC Working Group Health and Care and IQVIA. This event brings healthcare professionals together to learn about the possibilities of AI in the healthcare sector. The congress has no profit motive. This is important to the NL AIC, so that participation among care providers becomes as high as possible. During this congress you will discover how AI can contribute to more efficient care processes, reduce administrative burdens and address ethical and legal issues surrounding AI. The carefully composed program, developed by a scientific steering group, offers practical examples of successful AI projects and valuable insights that are directly applicable to your work. Register the program 09: 00-10: 00 Reception and coffee 10: 00-10:30 AM History, Impact and Future | Diederik Gommers, Intensivist & department head Intensive Care, Erasmus MC 10: 30 - 11:00
Read more
2025-03-18 (healthaffairs.org)
Copay Accumulator And Maximizer Programs: Stakes Rise For Patients As Federal Rulemaking Lags | Health Affairs Forefront
Copayment accumulators and maximizers have the potential to harm patients' access to necessary medicines. Health care payers (including employers, insurers, and pharmacy benefit managers), regulators, and policy makers should take swift action to curtail the use of these programs.
Read more
2025-03-10 (stocktitan.net)
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services | IQV Stock News
IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:Deep clinical and DCT implementation strategy expertise across therapeutic areasHealthcare-grade AI implementation across the value chainNovel GenAI tools for enhanced patient experienceCountry-wise regulatory strategy expertiseDecentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.
Read more